Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 28.02% as Wall Street Analysts Expect?Zacks Investment Research • 08/07/26
Iovance: Stock Soars On Q2 Earnings - Critical Data In Melanoma, NSCLC Due SeptemberSeeking Alpha • 08/06/26
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/06/26
Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate UpdatesGlobeNewsWire • 08/06/26
Will Iovance Biotherapeutics (IOVA) Report Negative Q2 Earnings? What You Should KnowZacks Investment Research • 07/30/26
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026GlobeNewsWire • 07/30/26
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 07/04/26
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 06/23/26
Iovance's Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in AustraliaGlobeNewsWire • 06/03/26
Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For?The Motley Fool • 06/02/26
Iovance Biotherapeutics pushes cell therapy platform into solid tumor marketProactive Investors • 06/01/26
Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001GlobeNewsWire • 06/01/26
AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?Zacks Investment Research • 05/28/26
Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/07/26
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate UpdatesGlobeNewsWire • 05/07/26
Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 04/30/26